Lonza, BioWa Sign Licensing Agreement - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Lonza, BioWa Sign Licensing Agreement



BioWa and Lonza have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which  MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System.  The GS System includes Lonza’s host cell line, CHOK1SV.  Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by improving antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.

MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent Technology.   Today’s agreement incorporates Lonza’s technology to the existing Potelligent Technology.

Source: Lonza

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here